Company intelligence / Profile preview

Cleancard

London, England, United Kingdomcleancard.bio ↗

Ownership: Private
Development stage: Preclinical

Overview

Cleancard has developed a proprietary at-home rapid test platform that uses synthetic biology and artificial intelligence to detect multiple cancer biomarkers from urine within 30 minutes. The technology is designed for early detection of cancers such as prostate, bladder, and ovarian. The company claims successful targeting of 10 new cancer biomarkers during its Y Combinator batch but has not yet reported clinical trial results or commercial launch data.

Therapeutic areas: Oncology
Modalities: Synthetic biology-based diagnosticsDevice (at-home rapid test)
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Cleancard.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cleancard.

Explore the full profile